Movement Alert｜CSPC Pharmaceutical Rises 3.08% in Regular Trading, Breast Cancer Drug Combo Granted Breakthrough Designation Amid Institutional Accumulation

Market Focus07-16

On July 16, CSPC Pharmaceutical rose 3.08% in regular trading, trading at 8.52 HKD/share, with turnover of approximately 208 million HKD. The rally was driven by a cluster of positive developments including a breakthrough therapy designation and continued institutional buying.

On July 14, the company announced that its proprietary albumin-bound docetaxel combined with anbenitamab received breakthrough therapy designation from China's NMPA for the first-line treatment of unresectable or metastatic HER2-positive adult breast cancer. The designation followed positive Phase 3 results demonstrating significantly improved progression-free survival versus standard-of-care, with the company planning a near-term NDA submission.

On the institutional front, Huatai-PineBridge Fund purchased 7.368 million shares at approximately 8.14 HKD per share, totaling about 59.96 million HKD, while Orient Securities added 5.656 million shares at around 8.29 HKD. Additionally, the company recently received a $25 million R&D milestone payment from AstraZeneca under their strategic collaboration agreement for long-acting peptide drug development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145284195?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 09:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145284195","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CSPC Pharmaceutical Rises 3.08% in Regular Trading, Breast Cancer Drug Combo Granted Breakthrough Designation Amid Institutional Accumulation","media":"Market Focus","content":"<p><p>On July 16, CSPC Pharmaceutical rose 3.08% in regular trading, trading at 8.52 HKD/share, with turnover of approximately 208 million HKD. The rally was driven by a cluster of positive developments including a breakthrough therapy designation and continued institutional buying.</p><p>On July 14, the company announced that its proprietary albumin-bound docetaxel combined with anbenitamab received breakthrough therapy designation from China's NMPA for the first-line treatment of unresectable or metastatic HER2-positive adult breast cancer. The designation followed positive Phase 3 results demonstrating significantly improved progression-free survival versus standard-of-care, with the company planning a near-term NDA submission.</p><p>On the institutional front, Huatai-PineBridge Fund purchased 7.368 million shares at approximately 8.14 HKD per share, totaling about 59.96 million HKD, while Orient Securities added 5.656 million shares at around 8.29 HKD. Additionally, the company recently received a $25 million R&D milestone payment from AstraZeneca under their strategic collaboration agreement for long-acting peptide drug development.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC Pharmaceutical Rises 3.08% in Regular Trading, Breast Cancer Drug Combo Granted Breakthrough Designation Amid Institutional Accumulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC Pharmaceutical Rises 3.08% in Regular Trading, Breast Cancer Drug Combo Granted Breakthrough Designation Amid Institutional Accumulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-16 09:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 16, CSPC Pharmaceutical rose 3.08% in regular trading, trading at 8.52 HKD/share, with turnover of approximately 208 million HKD. The rally was driven by a cluster of positive developments including a breakthrough therapy designation and continued institutional buying.</p><p>On July 14, the company announced that its proprietary albumin-bound docetaxel combined with anbenitamab received breakthrough therapy designation from China's NMPA for the first-line treatment of unresectable or metastatic HER2-positive adult breast cancer. The designation followed positive Phase 3 results demonstrating significantly improved progression-free survival versus standard-of-care, with the company planning a near-term NDA submission.</p><p>On the institutional front, Huatai-PineBridge Fund purchased 7.368 million shares at approximately 8.14 HKD per share, totaling about 59.96 million HKD, while Orient Securities added 5.656 million shares at around 8.29 HKD. Additionally, the company recently received a $25 million R&D milestone payment from AstraZeneca under their strategic collaboration agreement for long-acting peptide drug development.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1145284195","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145284195","pubTimestamp":1784166823,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 16, CSPC Pharmaceutical rose 3.08% in regular trading, trading at 8.52 HKD/share, with turnover of approximately 208 million HKD. The rally was driven by a cluster of positive developments...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"走势预警|石药集团常规交易大涨3.08%，乳腺癌药物组合在机构积累中获得突破性认定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On July 16, CSPC Pharmaceutical rose 3.08% in regular trading, trading at 8.52 HKD/share, with turnover of approximately 208 million HKD. The rally was driven by a cluster of positive developments including a breakthrough therapy designation and continued institutional buying.On July 14, the company announced that its proprietary albumin-bound docetaxel combined with anbenitamab received breakthrough therapy designation from China's NMPA for the first-line treatment of unresectable or metastatic HER2-positive adult breast cancer. The designation followed positive Phase 3 results demonstrating significantly improved progression-free survival versus standard-of-care, with the company planning a near-term NDA submission.On the institutional front, Huatai-PineBridge Fund purchased 7.368 million shares at approximately 8.14 HKD per share, totaling about 59.96 million HKD, while Orient Securities added 5.656 million shares at around 8.29 HKD. Additionally, the company recently received a $25 million R&D milestone payment from AstraZeneca under their strategic collaboration agreement for long-acting peptide drug development.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145284195","isCrawlerRequest":true}